Benign Epilepsy in Children  by Chan, Sook-Cheng & Lee, Wang-Tso
134 J Formos Med Assoc | 2011 • Vol 110 • No 3
Contents lists available at ScienceDirect
Journal of the Formosan Medical Association
Journal homepage: http://www.jfma-online.com
J Formos Med Assoc 2011;110(3):134–144
Journal of the 
Formosan Medical Association
ISSN 0929 6646
Formosan Medical Association
Taipei, Taiwan
Volume 110 Number 3 March 2011
The Biobank act as a route to responsible research: A first step for Taiwan?
Commentary on chronic idiopathic urticaria in Taiwan
Benign epilepsy in children
Rat model of lumbar facet joint osteoarthritis 
Review Article
Benign Epilepsy in Children
Sook-Cheng Chan, Wang-Tso Lee*
The diagnosis of benign epilepsy syndrome should meet the following criteria: age-related and self-limited;
good response to medication; and no obvious neurological sequelae after seizure. However, the current
concept of benign epilepsy syndrome has been challenged because of the advancements in genetic studies,
neuroimaging, and molecular techniques. Many studies have revealed that the prevalence of behavioral
problems and learning difficulties as well as subtle cognitive deficits is higher among patients with benign
epilepsy, compared with the normal population. Here, we review updated results of these studies to show
the latest and broad comprehensive knowledge of benign epilepsy in children.
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rolandic epilepsy
The classification of benign epilepsy was not 
well clarified until 2001. The 2001 classification
(Commission on Classification and Terminology
of International League against Epilepsy, 2001)
proposed the definition of benign epilepsy syn-
drome as “a syndrome characterized by epilepsy
seizures that are easily treated, may not require
treatment, and may remit without sequelae”.1,2
Recently, more studies have revealed that a vari-
able percentage of defined benign epilepsy, such
as childhood absence seizure (CAE) and benign
childhood epilepsy with centrotemporal spikes
(BCECTS), can be drug-resistant despite a long-
term favorable outcome. Moreover, juvenile myo-
clonic epilepsy (JME) and late-onset childhood
occipital epilepsy (Gastaut type), which are con-
sidered to be benign epilepsy, might lead to life-
long drug dependence. The 2009 workshop of
the International League against Epilepsy (ILAE)
has proposed four features to define benign
epilepsy: (1) self-limited course with benign evo-
lution regardless of treatment; (2) no sequelae
for cognitive and brain development and quality
of life; (3) diagnosis at onset, and the clinical
and electroencephalography (EEG) criteria, or even
neuroimaging, predicting a benign evolution; and
(4) treatment not always necessary. The identi-
fication of these self-limited electroclinical syn-
dromes might have an important influence on
family and patient counseling.
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The main goal of classification of benign epi-
lepsy is to give an early reliable prognostic param-
eter during follow-up, and reassure and decrease
the anxiety of parents or caregivers. However, 
recent studies have raised the issue of subtle neu-
rocognitive deficit and behavioral comorbidity
in patients with benign epilepsy. Some of these
syndromes might also have atypical evolution
and even cause sudden death during ictal attack.
Therefore, the name benign epilepsy has been
challenged. In general, benign epilepsy should
have typical EEG or clinical features that predict
remission of seizures, with or without medication,
and less permanent impact on patients’ potential.
Hence, in 2009, ILAE categorized the following
seizures as benign epilepsy: benign non-familial
neonatal seizure; benign familial neonatal seizure;
benign familial infantile seizure; benign non-
familial infantile seizure; benign myoclonic epi-
lepsy in infancy; Panayiotopoulos syndrome (PS);
late-onset childhood occipital epilepsy (Gastaut
type); BCECTS; CAE (pure type); JME; and some
seizure syndromes in progress.1
In the present review, we focus on discussing
some specific benign epilepsy syndromes in chil-
dren. Advanced neuroimaging studies, such as
functional magnetic resonance image (fMRI),
positron emission tomography, or neuropsycho-
logical tests, as well as cohort studies designed
for clinical manifestations and responsiveness to
medication are reviewed (Table).
Benign Infantile Seizure
Benign infantile seizures were first described by
Fukuyama in 1963, and are characterized by ap-
parently generalized and symmetrical convul-
sions, without etiology or family history, and are
usually accompanied with normal psychomotor
development and EEG interpretation.3 They remit
with age, with or without medication. Watanabe
in 1987 introduced another partial epilepsy syn-
drome in infancy with complex partial seizure with
or without secondary generalization.4,5 Meanwhile,
Vigeveno in 1992 discovered infantile seizure with
family history.4,5 According to the ILAE report in
2001, epileptic syndromes with onset during the
first year of life are recognized in benign familial
infantile seizures and benign non-familial infan-
tile seizure. However, recent studies have found
that these two forms are identical in electroclini-
cal features, seizure onset and outcome, except
for family history.5 Hence, the ILAE Classification
Core Group in 2006 recognizes benign infantile
seizure, also called Fukuyama–Watanabe–Vigevano
syndrome, as one syndrome that occurs during
infancy.
Autosomal dominant inheritance with incom-
plete penetrance and genetic heterogeneity has
been demonstrated in the familial form of benign
infantile seizure. Four susceptibility loci have been
identified: chromosome 19q (Italian); 16p12-
q12 (worldwide); 2q24 (Italian); and 1p36.12-
p35.1 (newly found in a Chinese family).6–8 The
locus over chromosome 16 is mapped most fre-
quently. Recent data have shown that the 16p12-
q12 locus might be linked to some clinical features
of paroxysmal dyskinesia, which has led to the
concept of infantile convulsion and paroxysmal
choreoathetosis syndrome.9
Scheduled neurodevelopment assessment is
crucial for patients with benign infantile seizures.
However, long-term antiepileptic treatment for
several years is probably not required.
CAE
CAE was first recognized in 1924 as pyknolepsy,
with clinical presentation of frequent transient
impairment of consciousness.10 According to ILAE
in 1989, a diagnosis of CAE must meet the criteria
of: (1) occurring during school age (2–10 years of
age, with a peak at 6–7 years); (2) strong genetic
predisposition; (3) EEG manifesting with bilat-
eral, synchronous symmetric spike-waves, usu-
ally 3 Hz, on a normal background; and (4) very
frequent attacks (many times per day).10 How-
ever, because some of the atypical presentations of
CAE might lead to poorer prognosis, Loiseau and
Panayiotopoulos have proposed stricter criteria for
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CAE.11 The age is limited to 4–10 years and peaks
at 5–7 years. The absence is brief (4–20 seconds,
exceptionally longer) and frequent (tens of times
daily), with abrupt and severe impairment of
consciousness. Frequent automatism might occur.
EEG reveals complexes of rhythmic high ampli-
tude spikes and double spike-waves, with gradual
initiation and termination phases. Exclusion cri-
teria include: (1) generalized tonic–clonic seizures
(GTCSs) or myoclonic jerks before or during the
active stage of absence; (2) presence of eyelid
myoclonia, rhythmic massive limb jerking, peri-
oral myoclonia, and single or arrhythmic myo-
clonic jerks of head, trunk or limbs; (3) only mild
or no impairment of consciousness during the 
3- or 4-Hz discharge; (4) 3- or 4-Hz spike-waves
for less than 4 seconds, presence of multiple spikes
(more than 3), or ictal discharge fragmentations;
and (5) clinical presentation of visual and other
sensory precipitation. A cohort study that com-
pared the outcome of patients using 1989 and
2005 CAE criteria revealed a significantly better
outcome using the later criteria.11 However, the
classification criteria are still debated. Although
strict syndrome criteria might be helpful for the
prediction of prognosis, many patients remain
unclassified. Some new syndromes, which have
been excluded from CAE group according to the
new criteria, are recognized, such as idiopathic
generalized epilepsy (IGE) with absence of early
childhood, IGE with phantom absence, and peri-
oral myoclonia with absences.12
Although CAE is recognized as a benign and
self-remitting epilepsy syndrome, recent studies
have shown that the incidence of behavioral,
cognitive and linguistic comorbidity is higher in
patients with CAE. A cross-sectional study has re-
vealed that compared to normal controls, 25% of
children with CAE had subtle cognitive deficits,
43% had linguistic difficulties, and 61% had psy-
chiatric problems, particularly attention deficit
hyperactivity disorder and anxiety disorders.13,14
Using newer neuroimaging techniques, subtle
structural abnormalities are also detected in pa-
tients with CAE.15 Significantly smaller gray matter
volumes of left orbital frontal gyrus and bilateral
temporal lobe have been found in CAE patients,
and they might have negative effects on behav-
ior, cognition and language during brain devel-
opment.16 Neuroimaging using simultaneous
blood oxygen level dependent (BOLD) EEG dur-
ing fMRI has shown that 3-Hz generalized spike-
waves are associated with regional BOLD signal
decreases in parietal areas and the caudate nu-
cleus, along with BOLD signal increases in the
medial thalamus.17 The results have revealed that
BOLD signal change in the striato-thalamo-cortical
network in drug-naïve CAE patients is consistent
with pharmacologically treated adults with long-
standing epilepsy.18
As more new antiepileptic drugs (AEDs) are
introduced, the role of the old AEDs as the first-line
treatment for CAE has been challenged. However,
one observational study has revealed that etho-
suximide, which was developed in 1950, remains
the most effective AED, with complete seizure con-
trol in 40–60% of absence patients.18 Valproic
acid also shows significant efficacy. However, the
side effects of ethosuximide and valproic acid are
still a concern to some neurologists. More neu-
rologists now use newer AEDs that have fewer
side effects. Lamotrigine, a phenyltriazine deriva-
tive, probably acting on voltage-sensitive sodium
channels, is approved as an add-on treatment for
complex partial seizures, and has also been shown
to have equal efficacy to valproic acid in patients
with absence epilepsy.19 Levetiracetam, which is
used in generalized epilepsy, has been shown 
to be effective in 21.7% of patients with IGE.20
Topiramate has also been approved for use in gen-
eralized epilepsy, but more studies are needed on
its efficacy in CAE patients.21
Although CAE is defined as benign epilepsy,
more attention should be given to its subtle cog-
nitive, linguistic and behavioral problems. Early
intervention for comorbidity will probably im-
prove school performance and epilepsy outcome.
For patients whose seizures are intractable to med-
ication, EEG and clinical presentations should be
reevaluated to exclude atypical absence with poor
prognostic factors, such as GTCSs, and fragmented
or multiple spike-wave complexes in EEG.11
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JME
JME is a common, age-related epilepsy syndrome
that begins at 5–16 years, and is also categorized
in IGE. JME is characterized by a clinical triad:
(1) all patients might have myoclonic jerks on
awakening; (2) 90% of patients experience GTCSs;
and (3) one-third of patients might have absence
seizures. It is considered to be relatively benign,
because seizures can be controlled successfully
with a single AED. Previously, IGE was considered
to have no abnormalities in neuroimaging studies.
However, recent studies have shown that subtle
structural abnormalities might be present in IGE
patients, detected by magnetic resonance spec-
troscopy. Patients with JME might have a 10%
lower level of N-acetylaspartate in the frontal lobe,
which suggests mild dysfunction in this area.22,23
This hypothesis has been supported by poor 
performance of executive function on neuropsy-
chological test in JME patients with decreased N-
acetylaspartate.24 Several studies using voxel-based
morphometry also have revealed some minor
structural changes in gray matter, particularly in the
prefrontal cortex, corpus callosum, hippocampus,
frontobasal areas, bilateral superior mesiofrontal
area, and thalamus.25 Hence, structural abnormal-
ities might not be uncommon in JME patients.15
Furthermore, although intellectual abilities are
always normal in JME patients, they might score
significantly low in attention, mental flexibility,
immediate verbal memory, working memory,
control of inhibition, processing speed, verbal or
visual delayed memory, and naming and verbal
fluency in neuropsychological tests.26 Besides, they
also have psychiatric comorbidity, such as social
and behavioral disorders, emotional instability,
and disinhibition. Some studies have proposed the
concept of dysexecutive syndrome in JME patients,
which is characterized by dysfunction of the frontal
lobe that can result in deficits of abstract reason-
ing, concept formation, control of compulsivity,
and emotion.
Patients with JME have also been shown to have
impaired visual spatial memory. One study, which
investigated the changes in positron emission 
tomography during a visual spatial working me-
mory paradigm, revealed that JME patients fail 
to show an increase of glucose metabolism in
the dorsolateral prefrontal, premotor and basal
frontal cortices, compared to normal controls.27
By contrast, medial temporal structures might
play an important role during the task in JME pa-
tients. Therefore, JME patients might suffer from
cortical disorganization that affects frontal cog-
nitive function.27 However, another fMRI and
voxel-based morphometry study in 2009 failed
to reproduce the findings of frontal gray matter
changes and evidence of fMRI changes in work-
ing memory in JME patients.28 Therefore, the 
influence of the frontal lobe in JME remains con-
troversial. Further large, controlled studies using
advanced neuroimaging tools and detailed psy-
chological evaluation are needed to clarify these
points.
BCECTS
BCECTS (also called rolandic epilepsy), is the most
common focal seizure in childhood, and there is
a male predominance. The onset age ranges from
1 to 14 years, with a peak at 7–10 years. Most pa-
tients have unilateral facial sensory–motor and
oropharyngolaryngeal symptoms, hypersalivation,
and speech arrest. Loss of consciousness might
occur, and some patients might experience GTCSs.
About 75% of patients have seizures only during
sleep, and 10–13% have only one seizure. Almost
all seizures can remit by the age of 15–16 years.29–31
However, nearly 20% of patients can have intrac-
table seizures and have several seizures every day,
or even clusters of seizures.
Decisions about initiation of treatment or
withholding therapy are individualized. Some
authors have recommended delaying treatment
until patients have at least three seizures.32–34
Studies have revealed that more frequent seizures
and younger age of onset are correlated with poor
outcome, and treatment is probably needed. The
2006 ILAE treatment guidelines have shown that
“no AED have been proved as initial monotherapy
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in BCECTS patients at level A or level B efficacy
and effectiveness evidence”.2 Carbamazepine, val-
proic acid, phenobarbital, phenytoin and clonaz-
epam might have equivalent efficacy.35 Recently,
sulthiame has been revisited as an excellent med-
ication for normalization of EEG in BCECTS pa-
tients. A pilot study that transitioned BCECTS
children into levetiracetam monotherapy has dem-
onstrated improvement of language dysfunction,
particularly in auditory comprehensive and audi-
tory verbal memory.36 Nonetheless, most experts
agree to slowly taper the AEDs after a 1–3-year
seizure-free period, or after age is over 16 years.
The hallmark of EEG in BCECTS shows bipha-
sic, focal, sharp centrotemporal spikes (CTSs),
often followed by slow waves. The CTSs might
act as a subclinical marker with a strong genetic
influence and clinical phenotype. Indeed, more
than half of children with CTSs might not show
any clinical presentations, which suggests that
environmental and genetic factors play different
roles in the emergence of clinical symptoms.37–39
An association of BCECTS and CTSs with reading
or speech disability has been suggested. Some
authors have suggested that the endophenotype
of CTSs is linked to chromosome 15q14.40 Since
then, some studies have proved that the segrega-
tion ratio of CTSs in BCECTS families is consistent
with high penetration with autosomal dominant
inheritance. Recently, genome-wide study has dem-
onstrated linkage of CTSs to chromosome 11p13
and revealed that CTSs in BCECTS were associated
with variants in Elongator Protein Complex 4.41
This complex might play an important role in
gene transcription and tRNA modification, and
could be implicated in cell motility and immi-
gration, particularly in neurons during cortical
maturation. Furthermore, a rare syndrome that
combines the features of BCECTS and speech
dyspraxia with X-linked inheritance (RESDAX
syndrome) has been reported, and the possible
causative gene SRPX2 has been identified re-
cently.42 Furthermore, the interaction of SRPX2
with another receptor, called urokinase plasmin-
ogen activator receptor (uPAR), as well as other
partners, such as cathepsin B, has also been
found.42 The SRPX2/uPAR association might lead
to the pathogenesis of CTSs.43 To date, BCECTS,
the syndrome of continuous spikes and waves
during sleep (CSWS), and the Landau–Kleffner
syndrome, although having different clinical pre-
sentations, have been considered as part of a single
continuous spectrum of disorders.44 This con-
cept is supported by the linkage of CTSs between
cryptogenic epilepsy and CSWS. Moreover, the
SRPX2 gene can also be found in patients with
CSWS and Landau–Kleffner syndrome. More study
is needed to identify the common genetic back-
ground among these syndromes.
The high risk of reading disability, speech sound
disorder, and cognitive impairment in BCECTS is
now well established. The association of attention
impairment in BCECTS is influenced by pathol-
ogy, medication, sleep deprivation, and seizure
attacks, and is relevant to overlapping of neural
circuitry for attention networks and involvement
in generation of seizure attacks.45,46 Clarke et al47
have proved that reading difficulties are strongly
associated with BCECTS after adjustment for age
and sex. Similarly, speech sound disorder is also
comorbid in BCECTS patients and their relatives.47
Therefore, all the patients and their siblings with
BCECTS should be screened for reading difficul-
ties and speech sound disorder.
Since the seizure foci of BCECTS are proximal to
the classical language area, some authors have sug-
gested that language skills are affected broadly.48,49
However, some studies have described a selective
language deficit that involves sentence formation
or fluency in BCECTS, but comprehension and
naming are spared.50,51 According to the literature,
activation of processing meaningful speech is left-
hemisphere dominant, and encompasses the fron-
tal and temporoparietal areas before age 3 years.
fMRI studies have demonstrated that language-
related activation is less lateralized to the left
hemisphere in the anterior brain region in BCECTS
patients.52 This finding has been supported by
neuropsychological tests that have shown that
BCECTS patients fail to achieve high scores for
sentence production, which depends on the inte-
grity of the anterior aspect of the language axis.
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Children with BCECTS might also demonstrate
specific speech recognition impairments, partic-
ularly under adverse listening conditions such as
background noise.53 In auditory evoked poten-
tial recording, BCECTS patients might show no
significant difference in latency or amplitude of
early N100 cortical response, compared with nor-
mal controls. However, the mismatch negativity,
a pre-attentive index of cortical procession, is ab-
sent for speech but not tones in BCECTS pa-
tients, which indicates some dysfunction in the
non-primary auditory cortex.53 These behavioral
deficits cannot be attributed solely to attention
deficits. Therefore, some authors have suggested
that comprehensive auditory testing, using behav-
ioral and electrophysiological measures, is impor-
tant in BCECTS patients.
Comorbidity, particularly language deficits,
learning disabilities, auditory dysfunction, and
behavioral disorders among patients with BCECTS
are well documented, and therefore, intensive
and comprehensive evaluation is mandatory for
patients with BCECTS and their siblings.
PS
PS is a newly recognized epilepsy syndrome, de-
fined as early-onset benign childhood occipital
epilepsy, according to the ILAE task force in 2006.54
However, PS is not truly occipital epilepsy. The
clinical presentations, EEG and pathophysiological
aspects are far beyond the occipital cortex.55–57 The
clinical manifestations of PS are predominantly
autonomic symptoms, particularly emesis, whereas
consciousness and speech are preserved.58–60 Other
manifestations include pallor, mydriasis, cardio-
respiratory or thermoregulatory alterations, in-
continence, hypersalivation, and abnormal
intestinal motility. The duration of seizures may
range from 6 minutes to several hours. More than
half of the patients might experience autonomic
status epilepticus, and two-thirds of seizures
occur during sleep. PS can progress to convulsive
seizures. Awareness might be preserved initially, but
might be impaired or fluctuating if duration is
prolonged.61–63 Therefore, PS is frequently mis-
taken as a non-epileptic condition, such as syncope,
migraine, cyclic vomiting syndrome, encephalitis,
motion sickness, sleep disorder, or gastroenteritis.64
The EEG abnormalities in PS might emerge from
shifting or multiple cortical and subcortical areas,
with occipital dominance. In the general popula-
tion, the prevalence of PS is about two to three per
10,000, and both sexes are equally affected.29,58 PS
is a newly recognized epilepsy syndrome, there-
fore, the prevalence rate might be underestimated.
However, according to Panayiotopoulos, the pre-
valence of PS is up to 13% among children aged
3–6 years with one or more afebrile seizures.
The pathophysiology of PS and autonomic
status epilepticus is largely unknown. Autonomic
seizures, particularly ictus emeticus, are strongly
age-related and more common to childhood, they
can be attributed to a maturation-related suscep-
tibility of the central autonomic system. The epi-
leptogenic area of PS is wide, and might emerge
from multifocal cortical areas, with spreading to
the surrounding autonomic system, which is likely
to have a lower threshold than other cortical
areas to epileptogenic activation.65,66 Therefore,
seizures might remain autonomic in PS because
other cortical areas might fail to reach the epilep-
togenic threshold.59
PS is remarkably benign and most patients
experience less than five attacks throughout life.
Autonomic status epilepticus seldom causes neuro-
logic deficits. However, potentially life-threatening
cardiorespiratory arrest can occur. A recent con-
sensus has suggested that no evidence of prolonged
seizures in PS can lead to cerebral damage. There-
fore, regular AED treatment is not recommended
for patients whose seizures are not frequent, dis-
tressing, or affecting daily life. Rescue medication
with benzodiazepam (rectal diazepam or oral
midazolam) for autonomic status epilepticus has
been suggested.67 Therefore, recognition or cor-
rect diagnosis of autonomic status epilepticus in
PS is mandatory to prevent unnecessary and po-
tentially dangerous procedures, such as intubation
or multiple intravenous medications that can
cause cardiorespiratory depression.
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Idiopathic Childhood Occipital Epilepsy
of Gastaut
Idiopathic childhood occipital epilepsy of Gastaut
(ICOE-G) is a rare form of occipital epilepsy, and
accounts for 2–7% of benign childhood focal
seizures. The onset age ranges from 3 to 15 years,
with a peak at 8–11 years.29,68 The typical clinical
manifestations might present with elementary
visual hallucination or blindness. Consciousness
is intact during the visual symptoms, but can 
be impaired in the course of seizures. The visual
hallucinations have stereotypic appearance with
regard to locations, colors, morphologies and
movements. Mostly, the visual seizures are brief
(lasting for a few seconds to minutes), and fre-
quent (occurring several times daily to once
weekly or monthly), and happen predominantly
in a diurnal pattern. Postictal headache might
occur immediately, or 5–10 minutes after the
end of visual hallucinations. It makes ICOE-G
clinically undistinguishable from migraine.29,69
The characteristics of the visual hallucinations in
ICOE-G include: (1) rapid development within
seconds from onset to full image; (2) rapid move-
ment within seconds toward the center of the 
visual field; and (3) usually bright colors and circu-
lar in shape. They also last for only 1–3 minutes.
Typical interictal EEG manifests occipital parox-
ysms with fixing off sensitivity, but some patients
might only have occasional occipital spikes or
spikes only during sleep. For patients with suspi-
cious ICOE-G, high-resolution MRI is crucial to
distinguish it from symptomatic occipital epilepsy
that presents with the same clinical and EEG
manifestations.
The prognosis of ICOE-G is still unclear, al-
though most studies have revealed that 50–60%
of patients remit within 2–4 years of onset. In
general, seizures are well controlled with carba-
mazepine in 90% of patients. Prophylactic AEDs
are mandatory in ICOE-G patients for prevention
of frequent seizures and GTCSs.29,70 ICOE-G is
relatively rare; therefore, further studies to inves-
tigate the genetic or pathophysiological mecha-
nisms and prognostic factors are required.
Conclusions and Recommendations
Although brain imaging studies such as MRI or
computed tomography are not routinely required
for benign epilepsy in children, the possible pres-
ence of subtle structural abnormalities in these
epilepsy syndromes cannot be ignored. Further
large controlled studies are needed to clarify these
structural abnormalities and their influence on the
outcome and response to medication. For patients
who are refractory to medication or who have
atypical evolution, imaging studies are mandatory.
Although benign childhood epilepsy has good
prognosis generally, it can have a great impact on
the family. Therefore, parental and family coun-
seling is crucial to lower the anxiety and misun-
derstanding of the family. Family education for
management of seizures should be carried out once
the diagnosis is confirmed. Furthermore, there are
many practical, genetic, diagnostic, electrophysi-
ological and epidemiological issues that remain
to be resolved. More prospective, evidence-based
and multidisciplinary approaches are needed for
better care of these patients.
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